+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia



Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia



Bmc Medicine 13: 294



Safety and efficacy of primaquine against repeated attacks of Plasmodium vivax depends upon co-administered blood schizontocidal therapy in radical cure. We assessed primaquine (PQ) as hypnozoitocide when administered with dihydroartemisinin-piperaquine (Eurartesim®, DHA-PP) or artesunate-pyronaridine (Pyramax®, AS-PYR) to affirm its good tolerability and efficacy. A third arm, artesunate followed by primaquine, was not intended as therapy for practice, but addressed a hypothesis concerning primaquine efficacy without co-administration of blood schizontocide. During March to July 2013, an open-label, randomized trial enrolled Indonesian soldiers with vivax malaria at Sragen, Central Java, after six months duty in malarious Papua, Indonesia. No malaria transmission occurred at the study site and P. vivax recurrences in the 12 months following therapy were classified as relapses. A historic relapse control derived from a cohort of soldiers who served in the same area of Papua was applied to estimate risk of relapse among randomized treatment groups. Those were: 1) AS followed 2d later by PQ (0.5 mg/kg daily for 14d); 2) co-formulated AS-PYR concurrent with the same regimen of PQ; or 3) co-formulated DHA-PP concurrent with the same regimen of PQ. Among 532 soldiers, 219 had vivax malaria during the four months following repatriation to Java; 180 of these were otherwise healthy and G6PD-normal and enrolled in the trial. Subjects in all treatment groups tolerated the therapies well without untoward events and cleared parasitemia within three days. First relapse appeared at day 39 post-enrollment, and the last at day 270. Therapeutic efficacy of PQ against relapse by incidence density analysis was 92 % (95 %CI = 83-97 %), 94 %(95 %CI = 86-97 %), and 95 %(95 %CI = 88-98 %) when combined with AS, AS-PYR, or DHA-PP, respectively. This trial offers evidence of good tolerability and efficacy of PQ against P. vivax relapse when administered concurrently with DHA-PP or AS-PYR. These offer alternative partner drugs for radical cure with primaquine. The AS arm demonstrated efficacy with a total dose of 7 mg/kg PQ without concurrently administered blood schizontocide, another option when primaquine therapy is removed in time from the treatment of the acute malaria or applied presumptively without an attack. Current Controlled Trials ISRCTN82366390, assigned 20 March 2013.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058689788

Download citation: RISBibTeXText

PMID: 26654101

DOI: 10.1186/s12916-015-0535-9


Related references

Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. International Ophthalmology 39(8): 1767-1782, 2019

Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. Malaria Journal 17(1): 45, 2018

A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. Journal of Infectious Diseases 208(11): 1906-1913, 2013

A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. Malaria Journal 17(1): 321, 2018

Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008-2010). Journal of Travel Medicine 20(2): 134-136, 2013

Expanding the Use of Primaquine for the Radical Cure of Plasmodium vivax. Clinical Infectious Diseases 67(7): 1008-1009, 2018

Compliance with 14-day primaquine therapy for radical cure of vivax malaria - a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene 98(3): 168-173, 2004

Optimal primaquine use for radical cure of Plasmodium vivax and Plasmodium ovale malaria in Japanese travelers--A retrospective analysis. Travel Medicine and Infectious Disease 13(3): 235-240, 2016

Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malaria Journal 11: 280, 2012

Therapeutic failure of primaquine and need for new medicines in radical cure of Plasmodium vivax. Acta Tropica 160: 35-38, 2016

Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. American Journal of Tropical Medicine and Hygiene 62(3): 393-395, 2000

A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. American Journal of Tropical Medicine and Hygiene 82(4): 542-547, 2010

In vivo trial for evaluation of chloroquine sensitivity of Plasmodium vivax isolates from Rondonia and efficacy of a new therapeutic schedules of association with primaquine for the treatment of P vivax malaria. Memorias do Instituto Oswaldo Cruz 93(Suppl. 2): 59-60, 1998

Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. Malaria Journal 14: 426, 2015

Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrobial Agents and ChemoTherapy 57(3): 1128-1135, 2013